Senesco Technologies, Inc.

Changing Cancer Therapy

Leslie J. Browne, Ph.D. President & CEO

October 23rd, 2013

Certain statements included in this presentation are forward-looking statements within the meaning of

the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such

statements expressed or implied herein as a result of a variety of factors, including, but not limited to:

the Company’s ability to recruit patients for its clinical trial, the ability of the Company to consummate

additional financings; the development of the Company’s gene technology; the approval of the

Company’s patent applications; the successful implementation of the Company’s research and

development programs and collaborations; the success of the Company's license agreements; the

acceptance by the market of the Company’s products; the timing and success of the Company’s

preliminary studies, preclinical research and clinical trials; competition and the timing of projects and

trends in future operating performance, the Company’s ability to comply with the continued listing

standards of the NYSE/MKT, as well as other factors expressed from time to time in the Company’s

periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press

release should be read in conjunction with the Company’s periodic filings with the SEC. The forward-

looking statements contained herein are made only as of the date of this press release, and the

Company undertakes no obligation to publicly update such forward-looking statements to reflect

subsequent events or circumstances.

2

Safe Harbor Statement

About Senesco

Founded 1998

Located Bridgewater, NJ

9 employees

Focused on cancer therapeutics

Listed on OTC QB as SNTI

Senesco’s Gene Regulation Platform Technology

Senesco Technologies is a clinical stage biotech company specializing

in cancer therapeutics

Our proprietary gene regulation technology has demonstrated the ability to eliminate cancerous cells and protect healthy cells from premature death

The company is running a Phase 1b/2a trial with a product that treats B-cell cancers (which include multiple myelomia and non-Hodgkins B-cell lymphomas)

Trial sites include the Mayo Clinic and the Fred Hutchinson Cancer Research Center

The technology was developed over the last 15 years through the discovery that the genetic pathway for cell growth control, targeted by Senesco, is common to both plants and humans

Ticker: SNTI Stock Exchange: OTC QB Recent Price: $3.30

Stock Basics & Financial Summary

5

Capitalization Table as of October 21, 2013 Common Stock Outstanding 3,067,000 Preferred Stock 232,000 Options 278,000 Warrants Outstanding 283,000 Fully Diluted 3,860,000

Cash on Hand as of June 30, 2013, as adjusted $3,200,000 Current burn rate per quarter $1,200,000 Revolving secured credit line $2,300,000

Senesco’s Platform A novel therapeutic

approach based on gene regulation

6

Senesco’s Platform Targets B-cell Cancers

Multiple myeloma is an incurable cancer of plasma cells – “B-cell” cancer ~65,000 patients in the US Median survival time is 2½ to 5 years

Diffuse large B-cell lymphoma (DLBCL) Most commonly diagnosed lymphoma ~120,00 patients in the US ~ 50% of patients unresponsive to standard

therapy

Mantle cell lymphoma (MCL) ~30,000 patients in the US Aggressive tumor with poor outcomes

7

All orphan drug indications

Multiple Myeloma: Large Market & High Unmet Medical Need

Company Drug® 2012 Sales

Takeda Velcade $2,100 MM

Celgene Revlimid $3,770 MM

Celgene Thalomid $387 MM

Onyx Kyprolis ~$250 MM (1st year)

Multiple myeloma market projected at $6 billion by 2018

Turning on a Normal Regulatory Process

Lysine Protein – need to turn up

Activates programmed cell death (apoptosis)

Hypusine Protein – need to turn down

Stimulates cell growth

Senesco’s drug reprograms the cells to recognize the death message by modulating the levels of both proteins

9

These two proteins act as a biological switch to promote cell death or survival

Lysine

F5A protein

Lysine form stimulates cell death

aka “apoptosis”

amino acid Hypusine

protein Hypusine form stimulates survival

amino acid

protein

Lysine and hypusine proteins control cell death and growth

10

Proteins Regulate Cell Growth and Death

Lysine

F5A protein

Lysine form stimulates cell death

aka “apoptosis”

switch

amino acid Hypusine

protein Hypusine form

promotes survival

amino acid Arginine

Arginine form stimulates cell death

aka “apoptosis”

protein

Replace hypusine with arginine Switch from survival to cell death

Therapeutic Strategy: Our drug down-regulates the growth message and up-regulates the death message so

inducing cancer cells to die

11

Senesco’s Drug Candidate Changes Levels of Both Proteins

1. RNAi suppresses pro-survival hypusine form

2. DNA plasmid makes stable death message under control of B-cell specific promoter

3. Polymer (PEI) forms nanoparticle to protect RNA and DNA and deliver death message to target

SNS01-T nanoparticle ~ 40 x 70 nM

12

Our Drug Uses Nanotechnology

Pre-Clinical Results

Our drug platform modulates and has broad activity in most cancer cell lines tested in vitro

Efficacy in multiple in vivo disease models including melanoma (B16-F0) and lung (A549) cancer*

Efficacy in blood cancer models in mice

85-95% growth inhibition in B-Cell cancers Synergy with bortezomib and lenalidomide

* Gene Ther Mol Biol 12, 207-218 (2008)

14

Efficacy in Cancer Cell Lines and In Vivo Models

* *** *** ** *** *** *** *** *** ***

***

** **

* p < 0.05 (n = 3) ** p < 0.01 (n = 3) *** p < 0.001 (n = 3)

Last Injection

>90% Inhibition of Human Multiple Myeloma Tumors in Mice

15

Human multiple myeloma tumors reduced up to 95% by SNS01-T treatment

Tumor Growth Control

Significantly Improved Survival in Multiple Myeloma Model

17 * p < 0.05; ** p < 0.01; *** p < 0.001 (compared to control group; Logrank test)

EX31-RPMI 8226:Survival proportions

0 10 20 30 40 50 60 70 80 90 100 1100

10

20

30

40

50

60

70

80

90

100

Control NanoparticleSNS01-TLEN 50SNS01-T +LEN 50

Days of Treatment

Perc

ent s

urviv

al

***

**

**

RPMI 8226 Multiple Myeloma

Tumor Growth Inhibition 102 Day Survival

1. Lenalidomide 50mg 20% (p < 0.05)

2. SNS01-T 0.375mg 60% (p < 0.01) 3. SNS01-T+ LEN 50 100% (p < 0.001)

End of treatment

SNS01-T is better alone

Combined even better

Clinical Trial Status

Design Open-label, multiple-dose, dose-escalation Twice-weekly IV infusions for 6 weeks

Endpoints Safety and tolerability Pharmacokinetics Tumor response Time to relapse or progression

Clinical Sites Mayo Clinic, U Arkansas, Hackensack UMC, U West

Virginia, Seattle Cancer Care Alliance

Phase 1b/2a B-cell Cancer Study

19

10 patients enrolled in groups 1 and 2

Good tolerability and stable disease at lowest doses

2 patients had stable disease at weeks 3 & 6

1 patient remained stable 4 weeks post dosing No drug-related severe adverse events

No dose-limiting toxicities

Phase 1b/2a Interim Results from Groups 1 & 2

20

Phase 1b/2a group 3 is ongoing at 0.2 mg/Kg

• 0.2 mg/Kg is efficacious dose level in cancer models in mice

• 3 patients need to be completed

Recruitment Continuing at Next Dose Level

21

Clinical Development Plans

22

Group 3 results by 4Q-2013 Topline results of Phase 1b/2a in 1H-2014 Phase 2 initiation planned for 2H-2014

• Focus on multiple myeloma, mantle and diffuse large B-cell lymphomas

Corporate

Harlan W. Waksal, M.D. Chair, Former COO, Imclone Systems

Christopher Forbes Vice Chair, Forbes Media, LLC

John N. Braca Exec Director Controller, Iroko Pharma

Leslie J. Browne, Ph.D. Pres & CEO, former CEO Pharmacopeia

Warren Isabelle, CFA Founder, Ironwood Investment Mgmt

Thomas C. Quick Former Vice Chair, Quick & Reilly/Fleet

David Rector Principal David Stephen Group

Ruedi Stalder Former Exec Board Member Credit Suisse

John E. Thompson, Ph.D. Executive VP, R&D, FRS of Canada

Jack Van Hulst Operating Partner, SK Capital Partners

Board of Directors

24

World-class science and management team

Founder of ImClone, Dr. Harlan Waksal, is Chairman of the Board

Near-term clinical trial results from Phase 1b/2a study

6 billion dollar opportunity for multiple myeloma alone

Many additional applications in solid tumors, inflammation and Alzheimers 25

Summary

Corporate Information

Senesco Technologies, Inc. 721 Route 202/206, Suite 130

Bridgewater, NJ 08807 Phone: 908-864-4444

www.senesco.com OTCQB: SNTI

IR: RedChip Companies, Inc

Dave Gentry Phone: 800-RED-CHIP (733-2447), ext.104

Email: info@redchip.com 26